Page last updated: 2024-08-23

staurosporine and Neoplasms

staurosporine has been researched along with Neoplasms in 102 studies

Research

Studies (102)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	9 (8.82)	18.2507
2000's	45 (44.12)	29.6817
2010's	38 (37.25)	24.3611
2020's	10 (9.80)	2.80

Authors

Authors	Studies
Flajolet, M; Greengard, P; Meijer, L	1
Arries, S; Bauch, JL; Bouska, JJ; Claibone, A; Dalton, C; De Jong, R; Giranda, VL; Gong, J; Jakob, CG; Johnson, EF; Klinghofer, V; Li, Q; Li, T; Liu, X; Luo, Y; Marsh, KC; Oltersdorf, T; Rosenberg, SH; Shi, Y; Stoll, VS; Zhu, GD	1
Abrams, J; Des Jong, R; Dinges, J; Fisher, J; Giranda, VL; Gong, J; Jakob, CG; Johnson, EF; Klinghofer, V; Li, Q; Li, T; Liu, X; Luo, Y; Oltersdorf, T; Packard, G; Rosenberg, SH; Shi, Y; Song, X; Stoll, VS; Thomas, S; Woods, KW; Zhu, GD	1
Beharry, ZM; Knaak, C; Kraft, AS; Ma, J; McInnes, C; Smith, CD; Wang, W; Xia, Z	1
Chen, X; Chen, Y; Gao, C; Jiang, Y; Li, Y; Liu, H; Luan, X; Tan, C; Zhang, C	1
Cole, D; Denny, R; Gopalsamy, A; Hall, JP; Hu, Y; Ipek, M; Lee, J; Lin, LL; Liu, J; Luong, M; Ni, Y; Telliez, JB	1
Hayano, M; Shimada, K; Skouta, R; Stockwell, BR	1
Jia, Y; Li, X; Wang, X; Wen, Q; Xu, F; Xu, W; Zhang, L; Zhang, Y	1
Hoda, N; Maqbool, M; Mobashir, M	1
Demicheli, C; Dittz, D; Frézard, F; Ishfaq, M; Islam, A; Marzano, IM; Paz Lopes, MT; Perreira-Maia, EC; Rodrigues, BL	1
Cheng, FX; Liao, CZ; Liu, XH; Shi, JB; Tang, WJ; Wang, Y; Yuan, XL	1
Cai, Z; He, R; Huang, W; Liu, S; Lv, X; Pan, J; Pan, X; Shao, Y; Sun, J; Xi, J; Zhang, J; Zhao, Y; Zhuang, R	1
Han, J; Lan, Z; Li, W; Tu, Y; Wang, C; Xu, S; Zheng, P; Zhou, Y; Zhu, W	1
Ghosh, U; Kharkar, PS; Khedkar, VM; Kulkarni, MR; Kulkarni-Almeida, A; Lad, NP; Mane, MS; Pandit, SS; Sharma, R; Srivastava, A	1
Bharate, SB; Joshi, P; Vishwakarma, RA	1
Chen, Y; Gao, L; Li, J; Lu, W; Shen, Q; Tong, L; Zhang, Q	1
Choi, MJ; Hur, W; Kim, JS; Lee, SH; Oh, CH; Roh, EJ; Sim, T; Yoo, KH	1
Bollinger, J; Budhraja, A; Craig, J; Lang, WH; Ling, T; Maier, J; Marsico, TD; Opferman, J; Potts, MB; Rivas, F	1
Abdel-Aziz, HA; Abou-Seri, SM; Bonardi, A; Eldehna, WM; Elgazar, AA; Fahim, SH; Gratteri, P; Kryštof, V; Nocentini, A; Said, MA; Soliman, DH; Supuran, CT	1
Davis, J; Gustafson, JL; Hecht, D; Marconi, GD; Michaels, H; Molina, B; Nefzi, A; Ortiz, MA; Piedrafita, FJ; Toenjes, S	1
Daelemans, D; De Jonghe, S; Dehaen, W; Hu, H; Krasniqi, B; Li, Y; Luyten, W; Persoons, L; Wang, R	1
Fan, L; Lei, F; Liu, Y; Sheng, K; Song, Y; Wu, L; Wu, S; Zhang, Y; Zhao, W	1
Dudenkova, VV; Gavrina, AI; Kovaleva, TF; Lukyanov, KA; Mozherov, AM; Shcheslavskiy, VI; Shirmanova, MV; Snopova, LB; Zagaynova, EV; Zelenova, EE	1
Angeli, A; El-Malah, A; Elbaramawi, SS; Ibrahim, TS; Mahmoud, Z; Moustafa, N; Supuran, CT; Taher, ES	1
Ahmad, SB; Aldossari, RM; Ali, A; Rashid, S; Rehman, MU	1
Li, P; Liu, X; Liu, Y; Qiu, Y; Yang, Y; Yin, Y	1
He, Y	1
Al Kafri, N; Hafizi, S	1
Hashimoto, M; Ishigaki, Y; Iwabuchi, K; Kamdar, RP; Matsui, T; Matsumoto, Y; Sakasai, R; Sharma, MK; Sunatani, Y	1
Asami, Y; Crump, A; Ōmura, S	1
Ambudkar, SV; Hsiao, SH; Hsu, SC; Huang, YH; Lusvarghi, S; Wu, CP	1
Doyle, A; Leanza, L; O'Reilly, P; Szabo, I; Szegezdi, E; Venturini, E; Zoratti, M	1
Blunt, M; Craggs, P; Hardwick, P; Hobbs, CI; Rowland, P; Shillings, A; Singh, O; Skarzynski, T; Smith, KJ; Tanner, R; Wall, I; Witty, DR	1
Antonopoulos, C; Dubyak, GR; El Sanadi, C; Kaiser, WJ; Mocarski, ES	1
Boren, J; Brindle, KM; Mahajan, S; Patel, II; Reichelt, S; Schreiner, A; Steuwe, C; Ul-Hasan, M	1
Hwang, ES; Na, YR; Seok, SH; Son, D	1
Dolznig, H; Hengstschläger, M; Kramer, N; Scherzer, M; Schwanzer-Pfeiffer, D; Unger, C; Unterleuthner, D; Walzl, A	1
Basrur, V; Chen, X; Chung, F; Elenitoba-Johnson, KS; Lim, MS; Pagano, M; Rangnekar, VM; Sahasrabuddhe, AA; Szankasi, P	1
Trendowski, M	1
Chen, WC; Li, SD; Roy, A; Tang, WL; Undzys, E	1
Huang, RC; Kimura, K	1
Altiok, S; Conway, AJ; Holton, AB; Kreahling, J; Landis, DA; Sinatra, FL	1
Giordano, A; Lapenna, S	1
Kuntz, K; O'Connell, MJ	1
Ambrose, EC; Kornbluth, J	1
Demidenko, E; Eastman, A; Hou, H; Khan, N; Lariviere, JP; Mupparaju, SP; Swartz, HM	1
Conley, BA; Dancey, J; Doroshow, JH; Figg, WD; Gardner, ER; Gutierrez, ME; Kummar, S; Melillo, G; Murgo, AJ; Sausville, EA	1
Brahimi-Horn, MC; Chiche, J; Gounon, P; Mazure, NM; Pouysségur, J; Rouleau, M	1
Amstutz, RA; Hecker, RM; Niggli, FK; Schäfer, BW; Wachtel, M; Walter, D	1
Bartek, J; Hasvold, G; Lukas, J; Petersen, L; Syljuåsen, RG	1
Adkins, DR; Arquette, MA; Cai, SR; Chen, RC; Creekmore, AN; Dancey, J; Ellis, MJ; Fleshman, JW; Fracasso, PM; Goodner, SA; Guo, Z; Lin, L; Ma, CX; McLeod, HL; Naughton, MJ; Picus, J; Piwnica-Worms, H; Pluard, TJ; Rader, JS; Rudek, MA; Ryan, CE; Soares, EM; Tan, BR; Tao, Y; Williams, KJ; Wright, LP	1
Mologni, L	1
Adamski, J; Halama, A; Möller, G	1
Gadet, R; Gillet, G; Gonzalo, P; Hesling, C; Lopez, J; Mikaelian, I; Popgeorgiev, N; Prudent, J; Rimokh, R	1
Chen, Y; Deng, X; Fang, Z; Lin, J; Sheng, F; Wei, Y; Xia, B; Zhong, W; Zhou, C; Zhou, J	1
Chi, HT; Kano, Y; Ly, BT; Sato, Y; Tojo, A; Watanabe, T	1
Senderowicz, AM	4
Swanton, C	1
Campbell, A; Clark, JW; Deluca, P; Eder, JP; Garcia-Carbonero, R; LoRusso, P; Puchalski, TA; Rothermel, J; Ryan, DP; Supko, JG; Wozniak, A	1
Lam, MH; Rosen, JM	1
Cao, P; Gronda, M; Hedley, DW; Jacobberger, JW; Pham, NA; Schimmer, AD	1
Altieri, DC; Beltrami, E; Dohi, T; Plescia, J; Wall, NR	1
Acharya, MR; Chen, H; Figg, WD; Headlee, D; Kuwabara, T; Messmann, RA; Murgo, AJ; Sausville, EA; Senderowicz, AM; Sparreboom, A; Venzon, DJ	1
Sausville, EA	1
Gonen, M; Ilson, DI; Kaubisch, A; Kelsen, DP; Kemeny, N; Kortmansky, J; Maki, RG; O'reilly, E; Saltz, LB; Schwartz, GK; Shah, MA; Sowers, R; Tong, W; Weyerbacher, A; Yi, S	1
Aylesworth, C; Baker, SD; Carducci, MA; Davidson, SB; Dees, EC; Donehower, RC; Elza-Brown, K; O'Reilly, S; Rudek, MA	1
Blagden, S; de Bono, J	1
Shi, HY; Zhang, M; Zhang, W	1
Doroshow, JH; Frankel, P; Gandara, DR; Gumerlock, PH; Lara, PN; Longmate, J; Mack, PC; Synold, T	1
Asanuma, H; Hata, F; Hirata, K; Hirohashi, Y; Kamiguchi, K; Kurotaki, T; Nabeta, C; Nakanishi, K; Ohmura, T; Sato, N; Sato, T; Torigoe, T; Tsuruma, T; Yamaguchi, K; Yamamoto, M	1
Baras, A; Chua, A; Maxhimer, JB; Nguyen, DM; Schrump, DS; Shamimi-Noori, S; Yeow, WS; Ziauddin, MF	1
Beaulieu, B; Beelen, AP; Eastman, A; Ernstoff, MS; Johnston, N; Lewis, LD; Olszanski, AJ; Perez, RP; Rhodes, CH	1
Baker, SD; Carducci, MA; Dancey, J; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, DA; Messersmith, WA; Purcell, T; Rudek, MA	1
Bauer, KS; Bisacia, S; Dancey, J; Edelman, MJ; Smith, R; Wu, S	1
Brüne, B; Geisslinger, G; Johann, AM; Schmidt, H; Tzieply, N; von Knethen, A; Weigert, A	1
Chen, XG; Zuo, MX	1
Barnes, JM; Cohen, MB; Henry, MD; Rokhlin, OW; Svensson, RU	1
Fassl, A; Gdynia, G; Lehmann-Koch, J; Matsuzawa, S; Reed, JC; Roth, W; Sieber, S; Tagscherer, KE; Zentgraf, H	1
Azuma, T; Chen, L; Flies, AS; Flies, SJ; Yao, S; Zhu, G	1
Eastman, A; Fanous, AA; Levesque, AA; Poh, A	1
Hakomori, S	1
Blume, E	1
Broxterman, HJ; Eekman, CA; Kuiper, CM; Lankelma, J; Pinedo, HM; Schuurhuis, GJ; Versantvoort, CH	1
Beltran, P; Fan, D; Fidler, IJ; Killion, JJ; O'Brian, CA; Wilson, MR; Yoon, SS	1
Baldwin, AS; Mayo, MW; Wang, CY	1
Lavelle, F	1
Blomhoff, HK; Jonassen, TS; Skarstad, K; Smedshammer, L; Steen, HB; Stokke, T	1
Amarante-Mendes, GP; Cotter, TG; Finucane, DM; Green, DR; Martin, SJ; Salvesen, GS	1
Balkwill, F; Braybrook, J; Caponigro, F; Dobbs, N; Fabbro, D; Ganesan, T; Harris, A; Hutchison, C; Man, A; McDonald, A; Propper, D; Talbot, D; Thavasu, P; Twelves, C	1
Sausville, EA; Senderowicz, AM	1
Bodis, S; Campochiaro, P; Csermak, K; Fabbro, D; Man, A; Meyer, T; O'Reilly, T; Pruschy, M; Ruetz, S; Wood, J	1
Darzynkiewicz, Z	1
Bodis, S; Fabbro, D; Glanzmann, C; Lowe, SW; Pruschy, M; Rocha, S; Soengas, MS; Winterhalter, K	1
Bodis, S; Fisher, DE; Glanzmann, C; Hess, C; Pruschy, M; Rocha, S; Tenzer, A; Zaugg, K	1
Balkwill, F; Blackie, R; Braybrooke, JP; Caponigro, F; Dutreix, C; Ganesan, TS; Graf, P; Harris, AL; Kaye, SB; Man, A; McDonald, AC; Propper, DJ; Talbot, DC; Thavasu, P; Twelves, C	1
Arbuck, SG; Bauer, KS; Figg, WD; Fuse, E; Headlee, D; Jaken, S; Jing , X; Kuwabara, T; Lahusen, T; Lush, RM; Messmann, R; Murgo, A; Roberge, M; Sausville, EA; Senderowicz, AM	1
Engels, IH; Janssen, O; Kabelitz, D; Lauber, K; Schulze-Osthoff, K; Stepczynska, A; Wesselborg, S	1
Carter, CA	1
Borner, C; Gilb, B; Kaufmann, T; Kersten, A; Kirkin, V; Kiss, J; Schempp, CM; Simon, JC; Simon-Haarhaus, B; Sleeman, JP; Termeer, CC	1

Reviews

19 review(s) available for staurosporine and Neoplasms

Article	Year
Pharmacological inhibitors of glycogen synthase kinase 3. Trends in pharmacological sciences, 2004, Volume: 25, Issue:9 Topics: Animals; Cell Differentiation; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Humans; Neoplasms; Nervous System Diseases; Parasitic Diseases; Signal Transduction; Stem Cells; Structure-Activity Relationship	2004
Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease. European journal of medicinal chemistry, 2016, Jan-01, Volume: 107 Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Diabetes Mellitus; Glycogen Synthase Kinase 3; Hippocampus; Humans; Hypoglycemic Agents; Inflammation; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors	2016
Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer. European journal of medicinal chemistry, 2017, Sep-29, Volume: 138 Topics: Alkaloids; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Products; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship	2017
Research progress in pharmacological activities and structure-activity relationships of tetralone scaffolds as pharmacophore and fluorescent skeleton. European journal of medicinal chemistry, 2022, Jan-05, Volume: 227 Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bacteria; Fluorescent Dyes; Humans; Molecular Structure; Neoplasms; Tetralones	2022
Staurosporine: new lease of life for parent compound of today's novel and highly successful anti-cancer drugs. The Journal of antibiotics, 2018, Volume: 71, Issue:8 Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bacteria; Bacterial Infections; Carbazoles; Drug Discovery; Furans; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Staurosporine	2018
Exploiting the cytoskeletal filaments of neoplastic cells to potentiate a novel therapeutic approach. Biochimica et biophysica acta, 2014, Volume: 1846, Issue:2 Topics: Cytochalasins; Cytoskeleton; Depsipeptides; Humans; Indole Alkaloids; Neoplasms; Staurosporine	2014
Cell cycle kinases as therapeutic targets for cancer. Nature reviews. Drug discovery, 2009, Volume: 8, Issue:7 Topics: Animals; Aurora Kinases; Cell Cycle; Cell Cycle Proteins; Cyclin-Dependent Kinases; DNA Damage; Humans; Neoplasms; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Retinoblastoma-Like Protein p130; Staurosporine	2009
The G(2) DNA damage checkpoint: could this ancient regulator be the Achilles heel of cancer? Cancer biology & therapy, 2009, Volume: 8, Issue:15 Topics: Antineoplastic Agents; Biological Evolution; Cell Cycle Proteins; Checkpoint Kinase 1; Conserved Sequence; DNA Damage; DNA, Neoplasm; DNA, Single-Stranded; Drug Delivery Systems; G2 Phase; Genes, cdc; Humans; Neoplasm Proteins; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Replication Protein A; Schizosaccharomyces; Schizosaccharomyces pombe Proteins; Species Specificity; Staurosporine	2009
Development of RET kinase inhibitors for targeted cancer therapy. Current medicinal chemistry, 2011, Volume: 18, Issue:2 Topics: Antineoplastic Agents; Humans; Indoles; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrimidines; Quinazolines; Staurosporine; Urea	2011
The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. The oncologist, 2002, Volume: 7 Suppl 3 Topics: Alkaloids; Animals; Antineoplastic Agents; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinases; Enzyme Inhibitors; Flavonoids; Humans; Neoplasms; Piperidines; Staurosporine	2002
Cyclin-dependent kinases as new targets for the prevention and treatment of cancer. Hematology/oncology clinics of North America, 2002, Volume: 16, Issue:5 Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Differentiation; Clinical Trials, Phase I as Topic; Cyclin-Dependent Kinases; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Flavonoids; Humans; Neoplasm Proteins; Neoplasms; Piperidines; Signal Transduction; Staurosporine; Transcription, Genetic	2002
Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms. Cancer chemotherapy and pharmacology, 2003, Volume: 52 Suppl 1 Topics: Alkaloids; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinases; Enzyme Inhibitors; Flavonoids; Humans; Neoplasms; Piperidines; Staurosporine; Tumor Cells, Cultured	2003
Cell-cycle targeted therapies. The Lancet. Oncology, 2004, Volume: 5, Issue:1 Topics: Animals; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme Inhibitors; Flavonoids; Humans; Neoplasms; Piperidines; Staurosporine	2004
Chk1 versus Cdc25: chking one's levels of cellular proliferation. Cell cycle (Georgetown, Tex.), 2004, Volume: 3, Issue:11 Topics: Animals; Antineoplastic Agents; cdc25 Phosphatases; Cell Cycle Proteins; Cell Proliferation; Checkpoint Kinase 1; Clinical Trials as Topic; Humans; Mice; Models, Biological; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Staurosporine	2004
Drugging cell cycle kinases in cancer therapy. Current drug targets, 2005, Volume: 6, Issue:3 Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Binding Sites; Cyclin-Dependent Kinases; Flavonoids; Humans; Neoplasms; Oxazoles; Piperidines; Protein Kinase Inhibitors; Purines; Roscovitine; Staurosporine; Sulfonamides; Thiazoles	2005
Inhibitors of cyclin-dependent kinase modulators for cancer therapy. Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques, 2005, Volume: 63 Topics: Animals; Antineoplastic Agents; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinases; Flavonoids; Humans; Neoplasms; Piperidines; Protein Kinase Inhibitors; Staurosporine	2005
[Research on cyclin-dependent kinase inhibitors: state of the art and perspective]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:5 Topics: Animals; Antineoplastic Agents; Cell Cycle; Cyclin-Dependent Kinases; Cyclins; Flavonoids; Humans; Neoplasms; Piperidines; Purines; Roscovitine; Staurosporine	2007
Preclinical and clinical development of cyclin-dependent kinase modulators. Journal of the National Cancer Institute, 2000, Mar-01, Volume: 92, Issue:5 Topics: Alkaloids; Animals; Antineoplastic Agents; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinases; Enzyme Inhibitors; Flavonoids; Humans; Neoplasms; Piperidines; Staurosporine	2000
Protein kinase C as a drug target: implications for drug or diet prevention and treatment of cancer. Current drug targets, 2000, Volume: 1, Issue:2 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Drug Delivery Systems; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Isoenzymes; Lung Neoplasms; Neoplasm Proteins; Neoplasms; Oligonucleotides, Antisense; Protein Kinase C; Retinoids; Staurosporine; Tretinoin	2000

Trials

14 trial(s) available for staurosporine and Neoplasms

Article	Year
Platelet-derived growth factor-C (PDGF-C) induces anti-apoptotic effects on macrophages through Akt and Bad phosphorylation. The Journal of biological chemistry, 2014, Feb-28, Volume: 289, Issue:9 Topics: Apoptosis; bcl-Associated Death Protein; Caspases; Cell Line, Tumor; Enzyme Activation; Enzyme Inhibitors; Female; Gene Knockdown Techniques; Humans; Lymphokines; Macrophages; Male; Neoplasms; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-akt; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Staurosporine	2014
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Prednisone; Staurosporine; Young Adult	2010
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Staurosporine; Young Adult	2011
A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. Investigational new drugs, 2004, Volume: 22, Issue:2 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Staurosporine	2004
Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Oct-15, Volume: 10, Issue:20 Topics: Antineoplastic Agents; Female; Half-Life; Humans; Infusions, Intravenous; Male; Neoplasms; Orosomucoid; Staurosporine	2004
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Mar-20, Volume: 23, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Female; Fluorouracil; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome	2005
A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jan-15, Volume: 11, Issue:2 Pt 1 Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase C; Salvage Therapy; Staurosporine; Time Factors	2005
The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jun-15, Volume: 11, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Atrial Fibrillation; Blotting, Western; cdc25 Phosphatases; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Cisplatin; Cyclin B; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Deglutition Disorders; Dose-Response Relationship, Drug; Female; Humans; Hyponatremia; Infections; Male; Middle Aged; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Renal Insufficiency; Staurosporine; Tachycardia; Treatment Outcome; Tumor Suppressor Proteins	2005
Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Dec-01, Volume: 12, Issue:23 Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Cell Cycle; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Injections, Intravenous; Maximum Tolerated Dose; Neoplasms; Predictive Value of Tests; Staurosporine; Tissue Distribution; Treatment Outcome	2006
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Staurosporine; Topoisomerase I Inhibitors	2008
Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, May-01, Volume: 13, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Synergism; Female; Humans; Male; Middle Aged; Neoplasms; Staurosporine	2007
The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients. Cancer research, 1999, Aug-15, Volume: 59, Issue:16 Topics: Adult; Aged; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinases; Cytokines; Enzyme Inhibitors; Humans; Lymphocytes; Middle Aged; Mitogen-Activated Protein Kinase 1; Neoplasms; Protein Kinase C; Staurosporine	1999
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-01, Volume: 19, Issue:5 Topics: Administration, Oral; Adult; Aged; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Neoplasms; Staurosporine	2001
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8 Topics: Adult; Aged; Alkaloids; Antineoplastic Agents; DNA Damage; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hyperglycemia; Hypotension; Infusions, Intravenous; Lymphoma, Large B-Cell, Diffuse; Male; Melanoma; Middle Aged; Nausea; Neoplasms; Skin Neoplasms; Staurosporine; Vomiting	2001

Other Studies

69 other study(ies) available for staurosporine and Neoplasms

Article	Year
Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation. Bioorganic & medicinal chemistry letters, 2006, Mar-15, Volume: 16, Issue:6 Topics: Adenosine Triphosphate; Antineoplastic Agents; Binding Sites; Calcium-Calmodulin-Dependent Protein Kinases; Cell Proliferation; Enzyme Inhibitors; Ethylenes; Glycogen Synthase Kinase 3; Humans; Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Structure-Activity Relationship	2006
Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer. Bioorganic & medicinal chemistry letters, 2006, Apr-01, Volume: 16, Issue:7 Topics: Antineoplastic Agents; Cell Line; Hydrogen Bonding; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Structure-Activity Relationship; X-Ray Diffraction	2006
Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. Journal of medicinal chemistry, 2009, Jan-08, Volume: 52, Issue:1 Topics: Animals; Antineoplastic Agents; Cell Line; Cell-Free System; Combinatorial Chemistry Techniques; Female; Humans; Kinetics; Mice; Mice, Inbred BALB C; Models, Molecular; Molecular Structure; Neoplasm Transplantation; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Structure-Activity Relationship; Thiazolidinediones	2009
Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors. Bioorganic & medicinal chemistry, 2011, Aug-01, Volume: 19, Issue:15 Topics: Antineoplastic Agents; Benzimidazoles; Cell Proliferation; Drug Discovery; ErbB Receptors; Hep G2 Cells; Humans; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2	2011
Identification and SAR of a new series of thieno[3,2-d]pyrimidines as Tpl2 kinase inhibitors. Bioorganic & medicinal chemistry letters, 2011, Oct-01, Volume: 21, Issue:19 Topics: Animals; Drug Discovery; Drug Evaluation, Preclinical; Humans; Inhibitory Concentration 50; MAP Kinase Kinase Kinases; Microsomes, Liver; Molecular Targeted Therapy; Monocytes; Neoplasms; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Rats; Structure-Activity Relationship; Substrate Specificity	2011
Design and synthesis of Pictet-Spengler condensation products that exhibit oncogenic-RAS synthetic lethality and induce non-apoptotic cell death. Bioorganic & medicinal chemistry letters, 2012, Sep-01, Volume: 22, Issue:17 Topics: Antineoplastic Agents; Carbolines; Cell Death; Cell Line, Tumor; Cell Survival; Drug Design; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Neoplasms	2012
Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: synthesis and biological evaluation. Part II. European journal of medicinal chemistry, 2013, Volume: 69 Topics: Angiogenesis Inhibitors; Animals; Aorta, Thoracic; Dose-Response Relationship, Drug; Drug Discovery; Human Umbilical Vein Endothelial Cells; Humans; Male; Models, Molecular; Molecular Structure; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Sulfonamides; Triazoles; Vascular Endothelial Growth Factor Receptor-2	2013
Cytotoxicity and apoptotic activity of novel organobismuth(V) and organoantimony(V) complexes in different cancer cell lines. European journal of medicinal chemistry, 2016, Feb-15, Volume: 109 Topics: Animals; Antimony; Antineoplastic Agents; Apoptosis; Bismuth; Cell Line; Cell Line, Tumor; Coordination Complexes; Crystallography, X-Ray; Humans; Mice; Models, Molecular; Neoplasms	2016
Dihydropyrazole derivatives as telomerase inhibitors: Structure-based design, synthesis, SAR and anticancer evaluation in vitro and in vivo. European journal of medicinal chemistry, 2016, Apr-13, Volume: 112 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Hep G2 Cells; Humans; Male; Mice; Molecular Docking Simulation; Neoplasms; Pyrazoles; Rats; Rats, Sprague-Dawley; Telomerase	2016
Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors. Bioorganic & medicinal chemistry, 2017, 06-15, Volume: 25, Issue:12 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridines; Pyrimidines	2017
Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors. Bioorganic & medicinal chemistry, 2017, 06-15, Volume: 25, Issue:12 Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Semicarbazones; Structure-Activity Relationship	2017
Discovery of tetrahydrocarbazoles as dual pERK and pRb inhibitors. European journal of medicinal chemistry, 2017, Jul-07, Volume: 134 Topics: Antineoplastic Agents; Carbazoles; Drug Discovery; Extracellular Signal-Regulated MAP Kinases; Humans; Molecular Docking Simulation; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Retinoblastoma Protein; Structure-Activity Relationship	2017
Pyrazolo[4,3-b]pyrimido[4,5-e][1,4]diazepine derivatives as new multi-targeted inhibitors of Aurora A/B and KDR. European journal of medicinal chemistry, 2018, Oct-05, Volume: 158 Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinase B; Azepines; Cell Line, Tumor; Humans; Mice; Mice, Nude; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Vascular Endothelial Growth Factor Receptor-2	2018
Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors. Bioorganic & medicinal chemistry letters, 2018, 12-15, Volume: 28, Issue:23-24 Topics: Amination; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Isoindoles; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases	2018
Studies of Jatrogossone A as a Reactive Oxygen Species Inducer in Cancer Cellular Models. Journal of natural products, 2019, 05-24, Volume: 82, Issue:5 Topics: Acetylcysteine; Antineoplastic Agents, Phytogenic; Antioxidants; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; Jatropha; Membrane Potential, Mitochondrial; Mitophagy; Neoplasms; Poly (ADP-Ribose) Polymerase-1; Reactive Oxygen Species	2019
Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation. European journal of medicinal chemistry, 2020, Mar-01, Volume: 189 Topics: Antineoplastic Agents; Azo Compounds; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; In Vitro Techniques; Molecular Docking Simulation; Molecular Structure; Neoplasms; Pyrazoles; Structure-Activity Relationship; Sulfonamides	2020
Discovery of cyclic guanidine-linked sulfonamides as inhibitors of LMTK3 kinase. Bioorganic & medicinal chemistry letters, 2020, 05-01, Volume: 30, Issue:9 Topics: Antineoplastic Agents; Combinatorial Chemistry Techniques; Drug Discovery; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Molecular Structure; Neoplasms; Protein Serine-Threonine Kinases; Small Molecule Libraries; Sulfonamides	2020
Antibacterial and antitumoral properties of 1,2,3-triazolo fused triterpenes and their mechanism of inhibiting the proliferation of HL-60 cells. European journal of medicinal chemistry, 2021, Nov-15, Volume: 224 Topics: Anti-Bacterial Agents; Antineoplastic Agents; Cell Proliferation; HL-60 Cells; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triterpenes	2021
Insight into redox regulation of apoptosis in cancer cells with multiparametric live-cell microscopy. Scientific reports, 2022, 03-16, Volume: 12, Issue:1 Topics: Apoptosis; Caspase 3; Cisplatin; Microscopy, Fluorescence; NAD; NADP; Neoplasms; Oxidation-Reduction; Reactive Oxygen Species; Staurosporine	2022
Schiff bases as linker in the development of quinoline-sulfonamide hybrids as selective cancer-associated carbonic anhydrase isoforms IX/XII inhibitors: A new regioisomerism tactic. Bioorganic chemistry, 2023, Volume: 131 Topics: Antigens, Neoplasm; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Humans; Molecular Structure; Neoplasms; Protein Isoforms; Quinolines; Schiff Bases; Staurosporine; Structure-Activity Relationship; Sulfonamides	2023
Computational Approaches for Identification of Potential Plant Bioactives as Novel G6PD Inhibitors Using Advanced Tools and Databases. Molecules (Basel, Switzerland), 2023, Mar-28, Volume: 28, Issue:7 Topics: Glucosephosphate Dehydrogenase; Humans; Molecular Dynamics Simulation; Neoplasms; Pentose Phosphate Pathway; Staurosporine	2023
Systematic profiling of staralog response to acquired drug resistant kinase gatekeeper mutations in targeted cancer therapy. Amino acids, 2020, Volume: 52, Issue:4 Topics: Antineoplastic Agents; Crystallography, X-Ray; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Molecular Targeted Therapy; Mutation; Neoplasms; Protein Conformation; Protein Kinase Inhibitors; Staurosporine	2020
Systematic response of staurosporine scaffold-based inhibitors to drug-resistant cancer kinase mutations. Archiv der Pharmazie, 2020, Volume: 353, Issue:6 Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Mutation; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Staurosporine; Structure-Activity Relationship	2020
Galectin-3 Stimulates Tyro3 Receptor Tyrosine Kinase and Erk Signalling, Cell Survival and Migration in Human Cancer Cells. Biomolecules, 2020, 07-11, Volume: 10, Issue:7 Topics: Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Blood Proteins; Cell Line, Tumor; Cell Movement; Cell Survival; Galectin 3; Galectins; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Neoplasms; Phosphorylation; Protein S; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Staurosporine; Triazoles	2020
Caspase-mediated cleavage of X-ray repair cross-complementing group 4 promotes apoptosis by enhancing nuclear translocation of caspase-activated DNase. Experimental cell research, 2018, 01-15, Volume: 362, Issue:2 Topics: Animals; Apoptosis; Cell Nucleus; Deoxyribonucleases; DNA Fragmentation; DNA Repair; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Humans; Jurkat Cells; Mice; Neoplasms; Paclitaxel; Protein Serine-Threonine Kinases; Serine-Arginine Splicing Factors; Signal Transduction; Staurosporine; Vincristine	2018
The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents. Cancer letters, 2019, 03-31, Volume: 445 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Repositioning; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Mice; Molecular Docking Simulation; Neoplasms; NIH 3T3 Cells; Protein Kinase Inhibitors; Staurosporine; Up-Regulation	2019
Correlation between potassium channel expression and sensitivity to drug-induced cell death in tumor cell lines. Current pharmaceutical design, 2014, Volume: 20, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Cisplatin; Gene Expression Regulation, Neoplastic; Humans; Kv1.1 Potassium Channel; Kv1.3 Potassium Channel; Mitochondria; Neoplasms; Potassium Channel Blockers; RNA, Messenger; Sphingosine; Staurosporine; Tumor Burden	2014
Crystal structures of ASK1-inhibtor complexes provide a platform for structure-based drug design. Protein science : a publication of the Protein Society, 2013, Volume: 22, Issue:8 Topics: Binding Sites; Cardiovascular Diseases; Crystallography, X-Ray; Drug Design; Humans; Ligands; MAP Kinase Kinase Kinase 5; Neoplasms; Neurodegenerative Diseases; Sf9 Cells; Signal Transduction; Staurosporine	2013
Proapoptotic chemotherapeutic drugs induce noncanonical processing and release of IL-1β via caspase-8 in dendritic cells. Journal of immunology (Baltimore, Md. : 1950), 2013, Nov-01, Volume: 191, Issue:9 Topics: Animals; Antibiotics, Antineoplastic; Apoptosis Regulatory Proteins; Calcium-Binding Proteins; CARD Signaling Adaptor Proteins; Carrier Proteins; Caspase 1; Caspase 8; Caspase Inhibitors; Caspases; Caspases, Initiator; Cytoskeletal Proteins; Dendritic Cells; Doxorubicin; Inhibitor of Apoptosis Proteins; Interleukin-1beta; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; NLR Family, Pyrin Domain-Containing 3 Protein; Staurosporine; Toll-Like Receptor 4; Ubiquitin-Protein Ligases	2013
CARS based label-free assay for assessment of drugs by monitoring lipid droplets in tumour cells. Journal of biophotonics, 2014, Volume: 7, Issue:11-12 Topics: Algorithms; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Drug Screening Assays, Antitumor; Etoposide; Fluorescent Dyes; HCT116 Cells; Humans; Lipid Droplets; Lipids; Microscopy, Fluorescence; Neoplasms; Spectrum Analysis, Raman; Staurosporine	2014
The Resazurin Reduction Assay Can Distinguish Cytotoxic from Cytostatic Compounds in Spheroid Screening Assays. Journal of biomolecular screening, 2014, Volume: 19, Issue:7 Topics: Antineoplastic Agents; Apoptosis; Biological Assay; Cell Communication; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Edetic Acid; Egtazic Acid; HT29 Cells; Humans; Microscopy, Confocal; Neoplasms; Oxazines; Spheroids, Cellular; Staurosporine; Xanthenes	2014
Fbxo45-mediated degradation of the tumor-suppressor Par-4 regulates cancer cell survival. Cell death and differentiation, 2014, Volume: 21, Issue:10 Topics: Amino Acid Sequence; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Survival; DEAD-box RNA Helicases; Enzyme Inhibitors; F-Box Proteins; HEK293 Cells; HeLa Cells; Humans; Molecular Sequence Data; Mutation; Neoplasms; Proteasome Endopeptidase Complex; Protein Binding; Protein Structure, Tertiary; RNA Interference; RNA, Small Interfering; Staurosporine; Ubiquitin-Protein Ligases; Ubiquitination	2014
A Simple and Improved Active Loading Method to Efficiently Encapsulate Staurosporine into Lipid-Based Nanoparticles for Enhanced Therapy of Multidrug Resistant Cancer. Pharmaceutical research, 2016, Volume: 33, Issue:5 Topics: Animals; Cell Line, Tumor; Dimethyl Sulfoxide; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Lipids; Liposomes; Mice, Inbred BALB C; Models, Molecular; Nanoparticles; Neoplasms; Particle Size; Protein Kinase Inhibitors; Staurosporine	2016
Tetra-O-Methyl Nordihydroguaiaretic Acid Broadly Suppresses Cancer Metabolism and Synergistically Induces Strong Anticancer Activity in Combination with Etoposide, Rapamycin and UCN-01. PloS one, 2016, Volume: 11, Issue:2 Topics: Antineoplastic Agents; Autophagy; Carbohydrate Metabolism; Caspase 7; Cell Line, Tumor; Down-Regulation; Drug Synergism; Energy Metabolism; Etoposide; Glutathione; Humans; Lipid Metabolism; Male; Masoprocol; Metabolic Networks and Pathways; Metabolome; Neoplasms; Oxidative Stress; Reactive Oxygen Species; Sirolimus; Staurosporine	2016
Microfluidic Biopsy Trapping Device for the Real-Time Monitoring of Tumor Microenvironment. PloS one, 2017, Volume: 12, Issue:1 Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Apoptosis; Biopsy; Cell Culture Techniques; Cell Proliferation; Doxorubicin; Enzyme Inhibitors; Female; Humans; Mice; Mice, Hairless; Mice, SCID; Microfluidic Analytical Techniques; Neoplasms; Staurosporine; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays	2017
Downregulation of uridine-cytidine kinase like-1 decreases proliferation and enhances tumor susceptibility to lysis by apoptotic agents and natural killer cells. Apoptosis : an international journal on programmed cell death, 2009, Volume: 14, Issue:10 Topics: Apoptosis; Caspase 3; Caspase 7; Cell Cycle; Cell Proliferation; Cytotoxicity, Immunologic; Down-Regulation; Etoposide; Gene Expression Regulation, Neoplastic; Gene Silencing; Green Fluorescent Proteins; Humans; K562 Cells; Killer Cells, Natural; Neoplasms; RNA, Messenger; RNA, Small Interfering; Staurosporine; Time Factors; Uridine Kinase	2009
Radiotherapy in conjunction with 7-hydroxystaurosporine: a multimodal approach with tumor pO2 as a potential marker of therapeutic response. Radiation research, 2009, Volume: 172, Issue:5 Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Electron Spin Resonance Spectroscopy; Female; Mice; Mice, Inbred C3H; Neoplasms; Oxygen; Staurosporine	2009
Hypoxic enlarged mitochondria protect cancer cells from apoptotic stimuli. Journal of cellular physiology, 2010, Volume: 222, Issue:3 Topics: Adenosine Triphosphate; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Hypoxia; Cell Proliferation; Drug Resistance, Neoplasm; Etoposide; GTP Phosphohydrolases; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Membrane Potential, Mitochondrial; Membrane Proteins; Membrane Transport Proteins; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Proteins; Mitochondrial Swelling; Neoplasms; Phenotype; Proto-Oncogene Proteins; RNA Interference; Staurosporine; Time Factors; Transfection; Tumor Suppressor Proteins	2010
p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment. Oncogene, 2010, Jul-08, Volume: 29, Issue:27 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Drug Synergism; Early Growth Response Protein 1; Female; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Genotype; Histone Deacetylase Inhibitors; Humans; Mice; Neoplasms; Paired Box Transcription Factors; Rhabdomyosarcoma, Alveolar; Staurosporine; Transcriptional Activation; Valproic Acid; Xenograft Model Antitumor Assays	2010
p53-dependent G(1) arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitors. Cell proliferation, 2010, Volume: 43, Issue:4 Topics: Cell Cycle; Cell Death; Cell Survival; Checkpoint Kinase 1; Colonic Neoplasms; Genes, p53; HCT116 Cells; Humans; Neoplasms; Nervous System Neoplasms; Protein Kinases; Radiation, Ionizing; Staurosporine; Tumor Suppressor Protein p53	2010
Metabolic signatures in apoptotic human cancer cell lines. Omics : a journal of integrative biology, 2011, Volume: 15, Issue:5 Topics: Apoptosis; Biomarkers; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Enzyme Activation; HEK293 Cells; Hep G2 Cells; Humans; Metabolome; Metabolomics; Neoplasms; Staurosporine	2011
Src tyrosine kinase inhibits apoptosis through the Erk1/2- dependent degradation of the death accelerator Bik. Cell death and differentiation, 2012, Volume: 19, Issue:9 Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis Regulatory Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Membrane Proteins; Mice; Mitochondrial Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasms; NIH 3T3 Cells; Oncogene Protein p21(ras); Proteolysis; raf Kinases; src-Family Kinases; Staurosporine; Thapsigargin	2012
Monitoring autophagic flux by an improved tandem fluorescent-tagged LC3 (mTagRFP-mWasabi-LC3) reveals that high-dose rapamycin impairs autophagic flux in cancer cells. Autophagy, 2012, Volume: 8, Issue:8 Topics: Animals; Autophagy; Cisplatin; Dose-Response Relationship, Drug; Embryo, Mammalian; Fibroblasts; Fluorescence; Green Fluorescent Proteins; HeLa Cells; Humans; Luminescent Proteins; Lysosomes; Mice; Microscopy, Confocal; Microtubule-Associated Proteins; Neoplasms; Recombinant Fusion Proteins; Red Fluorescent Protein; Sirolimus; Staurosporine	2012
ETV6-NTRK3 as a therapeutic target of small molecule inhibitor PKC412. Biochemical and biophysical research communications, 2012, Dec-07, Volume: 429, Issue:1-2 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Hematopoiesis; Humans; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Oncogene Proteins, Fusion; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; STAT5 Transcription Factor; Staurosporine	2012
The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. Molecular cancer therapeutics, 2004, Volume: 3, Issue:10 Topics: Animals; Anticarcinogenic Agents; Antigens; Apoptosis; Blotting, Western; Caspase 3; Caspase 8; Caspases; Cell Cycle; Cell Line, Tumor; Cell Membrane; Cell Nucleus; DNA; Dose-Response Relationship, Drug; Enzyme Activation; Flow Cytometry; Glutathione; Humans; Isothiocyanates; Male; Membrane Potentials; Mice; Mice, SCID; Microscopy, Fluorescence; Mitochondria; Mitosis; Neoplasm Transplantation; Neoplasms; Oxidative Stress; Pancreatic Neoplasms; Reactive Oxygen Species; Staurosporine; Sulfoxides; Thiocyanates; Time Factors; Tyrosine	2004
Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. The Journal of clinical investigation, 2004, Volume: 114, Issue:8 Topics: Animals; Apoptosis; Caspases; Cell Hypoxia; Cell Line, Tumor; Endopeptidase K; Enzyme Activation; Enzyme Inhibitors; HeLa Cells; Humans; In Situ Nick-End Labeling; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Mitochondria; Neoplasm Proteins; Neoplasms; Recombinant Fusion Proteins; Staurosporine; Subcellular Fractions; Survivin	2004
Indifferently pursued or unowned drugs: who should lead where companies do not tread? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Mar-20, Volume: 23, Issue:9 Topics: Antineoplastic Agents; Drug Industry; Humans; Neoplasms; Orphan Drug Production; Protein Kinase Inhibitors; Staurosporine	2005
Maspin overexpression modulates tumor cell apoptosis through the regulation of Bcl-2 family proteins. BMC cancer, 2005, May-20, Volume: 5 Topics: Animals; Apoptosis; Blotting, Western; Breast Neoplasms; Caspase 8; Caspase 9; Caspase Inhibitors; Cell Line; Cell Line, Tumor; Culture Media, Serum-Free; Cytochromes c; Cytosol; Disease Progression; DNA, Complementary; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Immunoblotting; Immunoprecipitation; In Situ Nick-End Labeling; Mice; Microscopy, Fluorescence; Models, Statistical; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Ribonucleases; Serpins; Staurosporine; Transcription, Genetic; Tumor Necrosis Factor-alpha	2005
A novel isoform of TUCAN is overexpressed in human cancer tissues and suppresses both caspase-8- and caspase-9-mediated apoptosis. Cancer research, 2005, Oct-01, Volume: 65, Issue:19 Topics: Adaptor Proteins, Signal Transducing; Adult; Amino Acid Sequence; Apoptosis; CARD Signaling Adaptor Proteins; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; fas Receptor; Fas-Associated Death Domain Protein; Humans; Jurkat Cells; Molecular Sequence Data; Neoplasm Proteins; Neoplasms; Protein Isoforms; Protein Structure, Tertiary; RNA, Messenger; RNA, Small Interfering; Staurosporine; Transfection	2005
Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01. British journal of cancer, 2006, May-22, Volume: 94, Issue:10 Topics: Anticonvulsants; Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Neoplasms; NF-kappa B; Staurosporine; Tumor Cells, Cultured; Valproic Acid	2006
Tumor cell apoptosis polarizes macrophages role of sphingosine-1-phosphate. Molecular biology of the cell, 2007, Volume: 18, Issue:10 Topics: Anti-Inflammatory Agents; Apoptosis; Cell Line, Tumor; Cell Polarity; Cell Survival; Coculture Techniques; Cytokines; Humans; Lysophospholipids; Macrophage Activation; Macrophages; Neoplasms; NF-kappa B; Phosphotransferases (Alcohol Group Acceptor); Sphingosine; Staurosporine	2007
Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy. Cancer research, 2007, Nov-01, Volume: 67, Issue:21 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cytomegalovirus; Doxorubicin; Humans; Luminescence; Male; Mice; Neoplasms; p38 Mitogen-Activated Protein Kinases; Promoter Regions, Genetic; Prostatic Neoplasms; Protein Biosynthesis; Staurosporine; Up-Regulation	2007
BLOC1S2 interacts with the HIPPI protein and sensitizes NCH89 glioblastoma cells to apoptosis. Apoptosis : an international journal on programmed cell death, 2008, Volume: 13, Issue:3 Topics: Adaptor Proteins, Signal Transducing; Adult; Amino Acid Sequence; Animals; Apoptosis; Caspase 3; Caspase 8; Cell Line, Tumor; Cytochromes c; Female; Glioblastoma; HeLa Cells; Humans; Immunohistochemistry; Male; Membrane Potential, Mitochondrial; Mitochondria; Molecular Sequence Data; Neoplasms; Protein Binding; Proteins; Sequence Alignment; Staurosporine; Tissue Distribution; TNF-Related Apoptosis-Inducing Ligand	2008
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood, 2008, Apr-01, Volume: 111, Issue:7 Topics: Animals; Antigens, Surface; Apoptosis; Apoptosis Regulatory Proteins; B7-1 Antigen; B7-H1 Antigen; Cell Line, Tumor; Enzyme Inhibitors; fas Receptor; Humans; Immunity, Cellular; Membrane Glycoproteins; Mice; Mice, Inbred DBA; Neoplasms; Peptides; Programmed Cell Death 1 Receptor; Signal Transduction; Staurosporine; T-Lymphocytes	2008
Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest. Molecular cancer therapeutics, 2008, Volume: 7, Issue:2 Topics: Camptothecin; Cell Cycle; Cell Proliferation; Checkpoint Kinase 1; Cyclin B; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; G2 Phase; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; S Phase; Signal Transduction; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2008
Novel endothelial cell activation factor(s) released from activated platelets which induce E-selectin expression and tumor cell adhesion to endothelial cells: a preliminary note. Biochemical and biophysical research communications, 1994, Sep-30, Volume: 203, Issue:3 Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alkaloids; Animals; Biological Factors; Cell Adhesion; Cell Adhesion Molecules; Cell Communication; Cells, Cultured; Colonic Neoplasms; E-Selectin; Endothelium, Vascular; Humans; Intercellular Adhesion Molecule-1; Isoquinolines; Kinetics; Lung Neoplasms; Melanoma, Experimental; Mice; Models, Biological; Naphthalenes; Neoplasms; Piperazines; Platelet Activation; Platelet Aggregation; Polycyclic Compounds; Protein Kinase Inhibitors; Protein Kinases; Staurosporine; Stomach Neoplasms; Tumor Cells, Cultured; Umbilical Veins	1994
Researchers gain footholds in the cell cycle. Journal of the National Cancer Institute, 1995, Oct-18, Volume: 87, Issue:20 Topics: Alkaloids; Animals; Antineoplastic Agents; Cell Cycle; DNA, Neoplasm; Humans; Neoplasms; Pentoxifylline; Staurosporine	1995
Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. British journal of cancer, 1993, Volume: 68, Issue:5 Topics: Alkaloids; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carrier Proteins; Daunorubicin; Doxorubicin; Drug Resistance; Etoposide; Genistein; Humans; Hydrogen-Ion Concentration; Isoflavones; Lung Neoplasms; Membrane Glycoproteins; Neoplasms; Protein-Tyrosine Kinases; Staurosporine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured	1993
The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251. Oncology research, 1995, Volume: 7, Issue:9 Topics: Administration, Oral; Animals; Antibiotics, Antineoplastic; Cell Line; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Fluorouracil; Injections, Intravenous; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Protein Kinases; Staurosporine; Tumor Cells, Cultured	1995
TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science (New York, N.Y.), 1996, Nov-01, Volume: 274, Issue:5288 Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Nucleus; Cycloheximide; Daunorubicin; DNA-Binding Proteins; Humans; I-kappa B Proteins; Interleukin-1; Leupeptins; Neoplasms; NF-kappa B; NF-KappaB Inhibitor alpha; Protein Synthesis Inhibitors; Radiation, Ionizing; Staurosporine; Transcription Factor RelA; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha	1996
[Tyrosine protein kinase inhibitors in cancerology: the end of the beginning?]. Bulletin du cancer, 1997, Volume: 84, Issue:7 Topics: Animals; ErbB Receptors; Humans; In Vitro Techniques; Male; Mice; Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Rats; Staurosporine; Structure-Activity Relationship	1997
Uncoupling of the order of the S and M phases: effects of staurosporine on human cell cycle kinases. Cell proliferation, 1997, Volume: 30, Issue:5 Topics: Cell Cycle; Cell Division; Cell Nucleus; Cells, Cultured; DNA; Fibroblasts; Genes, p53; Humans; Meiosis; Mitosis; Models, Biological; Neoplasms; Polyploidy; Protein Kinases; Retinoblastoma; Retinoblastoma Protein; S Phase; Staurosporine; Tumor Cells, Cultured	1997
Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell death. Cell death and differentiation, 1998, Volume: 5, Issue:4 Topics: Amino Acid Chloromethyl Ketones; Antibodies, Monoclonal; Apoptosis; Caspase Inhibitors; Caspases; Cysteine Proteinase Inhibitors; Dactinomycin; Enzyme Activation; Etoposide; fas Receptor; HL-60 Cells; Humans; Jurkat Cells; Neoplasms; Oncogenes; Staurosporine	1998
PKC412--a protein kinase inhibitor with a broad therapeutic potential. Anti-cancer drug design, 2000, Volume: 15, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Blood Proteins; Cell Cycle; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; Humans; Mice; Neoplasms; Protein Binding; Protein Kinase C; Staurosporine; Tumor Cells, Cultured	2000
Re: preclinical and clinical development of cyclin-dependent kinase modulators. Journal of the National Cancer Institute, 2000, Jul-19, Volume: 92, Issue:14 Topics: Animals; Antineoplastic Agents; Cell Cycle; Cyclin-Dependent Kinases; Drug Design; Enzyme Inhibitors; Humans; Neoplasms; Signal Transduction; Staurosporine	2000
Protein kinase C inhibitor and irradiation-induced apoptosis: relevance of the cytochrome c-mediated caspase-9 death pathway. Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research, 2000, Volume: 11, Issue:9 Topics: Animals; Apoptosis; Caspase 9; Caspases; Cytochrome c Group; Enzyme Inhibitors; Humans; Neoplasms; Protein Kinase C; Radiation Tolerance; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2000
Key targets for the execution of radiation-induced tumor cell apoptosis: the role of p53 and caspases. International journal of radiation oncology, biology, physics, 2001, Feb-01, Volume: 49, Issue:2 Topics: Adenoviridae; Animals; Apoptosis; Caspases; Cell Cycle; DNA Repair; Enzyme Activation; Enzyme Inhibitors; Genes, p53; Genetic Therapy; Genetic Vectors; Humans; Mice; Mice, Knockout; Neoplasm Proteins; Neoplasms; Staurosporine	2001
Staurosporine and conventional anticancer drugs induce overlapping, yet distinct pathways of apoptosis and caspase activation. Oncogene, 2001, Mar-08, Volume: 20, Issue:10 Topics: Antineoplastic Agents; Apoptosis; Caspases; Enzyme Activation; Etoposide; fas Receptor; HeLa Cells; Humans; Immunoblotting; Jurkat Cells; Mitochondria; Mitomycin; Neoplasms; Signal Transduction; Staurosporine; Transfection; Tumor Cells, Cultured	2001
Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. Oncogene, 2002, Feb-14, Volume: 21, Issue:8 Topics: Animals; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds; Caspases; Cell Division; Cytochrome c Group; Dose-Response Relationship, Drug; Enzyme Activation; Female; Humans; Hypericum; Intracellular Membranes; Microscopy, Electron; Mitochondria; Neoplasms; Phloroglucinol; Rats; Staurosporine; Terpenes; Time Factors; Tumor Cells, Cultured	2002